Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanai Health Industry Group Co (FRA:WUP0) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sanai Health Industry Group Co's Enterprise Value for the quarter that ended in Dec. 2025 was €-24.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanai Health Industry Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co EV-to-EBIT Related Terms
Sanai Health Industry Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:WUP0 vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanai Health Industry Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanai Health Industry Group Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanai Health Industry Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sanai Health Industry Group Co's EV-to-EBIT falls into.
Sanai Health Industry Group Co's current Enterprise Value is €-27.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sanai Health Industry Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanai Health Industry Group Co (FRA:WUP0) has a EV-to-EBIT of 9.47 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sanai Health Industry Group Co and its competitors. According to the industry distribution chart, Sanai Health Industry Group Co ranks #203 out of 694 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is Sanai Health Industry Group Co's EV-to-EBIT too high?
Sanai Health Industry Group Co's current EV-to-EBIT is 9.47. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Sanai Health Industry Group Co's value of 9.47 is 39.5% below this industry median. Based on the distribution chart, Sanai Health Industry Group Co ranks #203 out of 694 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanai Health Industry Group Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Sanai Health Industry Group Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sanai Health Industry Group Co ranks #203 out of 694 companies for EV-to-EBIT. This puts Sanai Health Industry Group Co in the upper half of its industry. The industry median EV-to-EBIT is 15.66. Sanai Health Industry Group Co's value of 9.47 is 39.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanai Health Industry Group Co's current EV-to-EBIT of 9.47 is 39.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sanai Health Industry Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanai Health Industry Group Co's current EV-to-EBIT is 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanai Health Industry Group Co stock overvalued right now?
Sanai Health Industry Group Co (FRA:WUP0) has a current EV-to-EBIT of 9.47. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 64.3% below its estimated fair value. The current EV-to-EBIT is 9.47 and 39.5% below the Drug Manufacturers industry median of 15.66. Sanai Health Industry Group Co's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sanai Health Industry Group Co (FRA:WUP0), the current EV-to-EBIT is 9.47 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanai Health Industry Group Co (FRA:WUP0) Overvalued in 2026?
Based on GuruFocus' analysis, Sanai Health Industry Group Co stock appears to be undervalued.
The current stock price of €0.03 is trading 64.3% below its estimated GF Value™ of €0.07.
Key valuation signals for FRA:WUP0:
EV-to-EBIT: 9.47
GF Value™: €0.07 vs. price of €0.03 (64.3% below fair value)
Industry Position: 39.5% below the Drug Manufacturers median (#203 of 694)
No single metric tells the full story. See the FRA:WUP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanai Health Industry Group Co Ltd is a pharmaceutical company. The company has three reportable segments namely Pharmaceutical products include development, manufacturing, marketing, and sales of pharmaceutical products and related software and provision of consultancy services. Finance leasing includes the provision of financial leasing services; Genetic testing and molecular diagnostic services segment. It generates maximum revenue from Pharmaceutical products segments. Geographically, it derives the majority of its revenue from the PRC.
38GF Score
Get the complete analysis for FRA:WUP0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WUP0 has been successfully added to your 
